C A Clarke1, S L Glaser, A W Prehn. 1. Surveillance Research, Northern California Cancer Center, Union City, CA 94587, USA. tclarke@nccc.org
Abstract
OBJECTIVE: To examine risk factors for disease-specific survival in young and older adults diagnosed with Hodgkin's disease (HD) in a representative case series of adequate size for detecting effect modification by age group. METHODS: For 5630 young adults (ages 15-44) and 2424 older adults (ages 45 and older) diagnosed with HD and reported to the population-based Surveillance, Epidemiology, and End Results program of the National Cancer Institute between 1983 and 1995, Kaplan-Meier survival curves were constructed and Cox proportional hazards regression used to evaluate the influences of age, sex, race/ethnicity, histologic subtype, Ann Arbor stage at diagnosis, and calendar year on hazard of disease-specific death. RESULTS: The effects of most previously studied risk factors for HD death were different for young and older adults. Age was not associated with disease-specific survival in young adults, but in older adults, 1-year increases in age elevated the relative hazard of HD death by 4 6%. Male sex was related to outcome in young but not older adults, and Ann Arbor stage and B-symptom status exhibited markedly different relationships to survival by age. Older adult patients with and without B-symptoms had different hazards of mortality and had to be assessed separately. CONCLUSIONS: Factors associated with disease-specific survival were different for young and older adults with HD. These findings provide further support for two etiologically and clinically distinct disease entities.
OBJECTIVE: To examine risk factors for disease-specific survival in young and older adults diagnosed with Hodgkin's disease (HD) in a representative case series of adequate size for detecting effect modification by age group. METHODS: For 5630 young adults (ages 15-44) and 2424 older adults (ages 45 and older) diagnosed with HD and reported to the population-based Surveillance, Epidemiology, and End Results program of the National Cancer Institute between 1983 and 1995, Kaplan-Meier survival curves were constructed and Cox proportional hazards regression used to evaluate the influences of age, sex, race/ethnicity, histologic subtype, Ann Arbor stage at diagnosis, and calendar year on hazard of disease-specific death. RESULTS: The effects of most previously studied risk factors for HD death were different for young and older adults. Age was not associated with disease-specific survival in young adults, but in older adults, 1-year increases in age elevated the relative hazard of HD death by 4 6%. Male sex was related to outcome in young but not older adults, and Ann Arbor stage and B-symptom status exhibited markedly different relationships to survival by age. Older adult patients with and without B-symptoms had different hazards of mortality and had to be assessed separately. CONCLUSIONS: Factors associated with disease-specific survival were different for young and older adults with HD. These findings provide further support for two etiologically and clinically distinct disease entities.
Authors: Mara M Epstein; Ellen T Chang; Yawei Zhang; Teresa T Fung; Julie L Batista; Richard F Ambinder; Tongzhang Zheng; Nancy E Mueller; Brenda M Birmann Journal: Am J Epidemiol Date: 2015-07-15 Impact factor: 4.897
Authors: Rachel L Yung; Kun Chen; Gregory A Abel; Foster C Gesten; Patrick J Roohan; Francis P Boscoe; Amber H Sinclair; Maria J Schymura; Deborah Schrag Journal: Oncologist Date: 2011
Authors: Theresa H M Keegan; Christina A Clarke; Ellen T Chang; Sarah J Shema; Sally L Glaser Journal: Cancer Causes Control Date: 2009-12 Impact factor: 2.506
Authors: Mara M Epstein; Sarah K Dutcher; Judith C Maro; Cassandra Saphirak; Sandra DeLuccia; Muthalagu Ramanathan; Tejaswini Dhawale; Sonali Harchandani; Christopher Delude; Laura Hou; Autumn Gertz; Nina DiNunzio; Cheryl N McMahill-Walraven; Mano S Selvan; Justin Vigeant; David V Cole; Kira Leishear; Jerry H Gurwitz; Susan Andrade; Noelle M Cocoros Journal: Pharmacoepidemiol Drug Saf Date: 2021-05-05 Impact factor: 2.732
Authors: Sally L Glaser; Christina A Clarke; Theresa H M Keegan; Ellen T Chang; Dennis D Weisenburger Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-27 Impact factor: 4.090
Authors: G L Jones; P R A Taylor; K P Windebank; N A Hoye; H Lucraft; K Wood; B Angus; S J Proctor Journal: Br J Cancer Date: 2007-05-29 Impact factor: 7.640